Home Featured Page 2

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Weekly Psychedelic Policy Briefing: August 23, 2026

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints...

Weekly Psychedelic Policy Briefing – August 9, 2026

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

Megan Bowers & Mikayla Hellwich: MDMA History, Harm Reduction, and the...

Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly;...

From Sonora to Big Pharma: Kimon de Greef Traces the Strange...

Psychedelic Alpha Crossword: Summer 2026

Weekly Psychedelic Policy Briefing – August 2, 2026

Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without...

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Weekly Psychedelic Policy Briefing: August 23, 2026

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints...

Weekly Psychedelic Policy Briefing – August 9, 2026

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

Megan Bowers & Mikayla Hellwich: MDMA History, Harm Reduction, and the...

Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly;...

From Sonora to Big Pharma: Kimon de Greef Traces the Strange...

Psychedelic Alpha Crossword: Summer 2026

Weekly Psychedelic Policy Briefing – August 2, 2026

Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without...

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY